Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia

References

• Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, ‘Just the facts’: what we know in 2008. Schizophr Res. 2008;100:4–19.
   PubMed Web of Science ®Google Scholar
• Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150:42–50.
   PubMed Web of Science ®Google Scholar
• Kalache SM, Mulsant BH, Davies SJC, Liu AY, Voineskos AN, Butters MA, et al. The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan. Schizophr Bull. 2015;41:374–81.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Keefe RSE. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70:1107–12.
   PubMed Web of Science ®Google Scholar
• Bora E, Binnur Akdede B, Alptekin K. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. 2017;47:2401–13.
   PubMed Web of Science ®Google Scholar
• Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80:168–76.
   PubMed Web of Science ®Google Scholar
• Milev P, Ho B-C, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495–506.
   PubMed Web of Science ®Google Scholar
• Gozdzik-Zelazny A, Borecki L, Pokorski M. Depressive symptoms in schizophrenic patients. Eur J Med Res. 2011;16(549).
   PubMedGoogle Scholar
• Bergman O, Ben-Shachar D. Mitochondrial oxidative phosphorylation system (OXPHOS) deficits in schizophrenia: possible interactions with cellular processes. Can J Psychiatry. 2016;61:457–69.
   PubMed Web of Science ®Google Scholar
• Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19:220–30.
   PubMed Web of Science ®Google Scholar
• Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Edden RA, et al. Elevated brain lactate in schizophrenia: a 7T magnetic resonance spectroscopy study. Transl Psychiatry. 2016;6(e967).
   PubMedGoogle Scholar
• Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta BBA – Biomembr. 2004;1660:171–99.
   PubMed Web of Science ®Google Scholar
• Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014;49:105–11.
   PubMedGoogle Scholar
• Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10. Neurobiol Dis. 2005;18:618–27.
   PubMed Web of Science ®Google Scholar
• Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci. 2012;13:293–307.
   PubMed Web of Science ®Google Scholar
• Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684–97.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang J-F, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci. 2006;31:189–96.
   PubMed Web of Science ®Google Scholar
• Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:101–14.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–4.
   PubMed Web of Science ®Google Scholar
• Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981–90.
   PubMed Web of Science ®Google Scholar
• Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA, et al. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry. 2009;65:489–94.
   PubMed Web of Science ®Google Scholar
• Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015;13(68).
   Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–16.
   PubMed Web of Science ®Google Scholar
• Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol. 2002;30:620–50.
   PubMed Web of Science ®Google Scholar
• Erecińska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab. 1989;9:2–19.
   PubMed Web of Science ®Google Scholar
• Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev. 1997;77:731–58.
   PubMed Web of Science ®Google Scholar
• Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, et al. Oxidative stress in neurodegenerative diseases. Mol Neurobiol. 2016;53:4094–125.
   PubMed Web of Science ®Google Scholar
• Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol. 2013;48:883–903.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–7.
   PubMed Web of Science ®Google Scholar
• Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42:261–4.
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541–50.
   PubMed Web of Science ®Google Scholar
• Müller T, Büttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. 2003;341:201–4.
   PubMed Web of Science ®Google Scholar
• The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20–8.
   PubMed Web of Science ®Google Scholar
• Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71:543–52.
   PubMed Web of Science ®Google Scholar
• Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol. 2007;64:938–44.
   PubMed Web of Science ®Google Scholar
• Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, et al. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:911–6.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–95.
   PubMed Web of Science ®Google Scholar
• Jodeiri Farshbaf M, Ghaedi K. Huntington’s disease and mitochondria. Neurotox Res. 2017;32:518–29.
   PubMed Web of Science ®Google Scholar
• Andrich J, Saft C, Gerlach M, et al. Coenzyme Q10 serum levels in Huntington’s disease. In: Müller T, Riederer P, editors. Focus extrapyramidal dysfunction. Vienna: Springer Vienna; 2004. p. 111–6.
   Google Scholar
• Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41:160–5.
   PubMed Web of Science ®Google Scholar
• Group HS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.
   PubMed Web of Science ®Google Scholar
• McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88:152–9.
   PubMed Web of Science ®Google Scholar
• Feigin A, Kieburtz K, Como P, Hickey C, Abwender D, Zimmerman C, et al. Assessment of coenzyme q10 tolerability in Huntington's disease. Mov Disord. 1996;11:321–3.
   PubMed Web of Science ®Google Scholar
• Stamelou M, de Silva R, Arias-Carrión O, Boura E, Hollerhage M, Oertel WH, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133:1578–90.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942–9.
   PubMed Web of Science ®Google Scholar
• Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, et al. Coq10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflammation. 2016;3(e266).
   PubMedGoogle Scholar
• Sadeghian M, Mastrolia V, Rezaei Haddad A, Mosley A, Mullali G, Schiza D, et al. Mitochondrial dysfunction is an important cause of neurological deficits in an inflammatory model of multiple sclerosis. Sci Rep. 2016;6(33249).
   PubMedGoogle Scholar
• Lazzarino G, Amorini A, Eikelenboom M, Killestein J, Belli A, Di Pietro V, et al. Cerebrospinal fluid ATP metabolites in multiple sclerosis. Multiple Sclerosis Journal. 2010;16:549–54.
   PubMed Web of Science ®Google Scholar
• Amorini AM, Nociti V, Petzold A, Gasperini C, Quartuccio E, Lazzarino G, et al. Serum lactate as a novel potential biomarker in multiple sclerosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2014;1842:1137–43.
   PubMed Web of Science ®Google Scholar
• van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45:1729–37.
   PubMed Web of Science ®Google Scholar
• Hargreaves I, Mody N, Land J, Heales S. Blood mononuclear cell mitochondrial respiratory chain complex IV activity is decreased in multiple sclerosis patients: effects of β-interferon treatment. J Clin Med. 2018;7(E36).
   Google Scholar
• Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478–89.
   PubMed Web of Science ®Google Scholar
• Sanoobar M, Dehghan P, Khalili M, Azimi A, Seifar F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: a double blind randomized clinical trial. Nutr Neurosci. 2016;19:138–43.
   PubMed Web of Science ®Google Scholar
• Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18:169–76.
   PubMed Web of Science ®Google Scholar
• Sanoobar M, Eghtesadi S, Azimi A,, Khalili M, Jazayeri S, Reza Gohari M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing–remitting multiple sclerosis. Int J Neurosci. 2013;123:776–82.
   PubMed Web of Science ®Google Scholar
• Moccia M, Annibali V, Lanzillo R, Cocozza S, Carotenuto A, Carotenuto B, et al. Oxidative stress in multiple sclerosis: effect of dietary supplementation with coenzyme Q10. Eur J Neurol. 2017;24:319.
   Google Scholar
• Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. Oxford University Press; 2007.
   Google Scholar
• Andreazza AC, Shao L, Wang J-F, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67:360–8.
   PubMed Web of Science ®Google Scholar
• Chu W-J, DelBello MP, Jarvis KB, Norris MM, Kim M-J, Weber Wade, et al. Magnetic resonance spectroscopy imaging of lactate in patients with bipolar disorder. Psychiatry Res Neuroimaging. 2013;213:230–4.
   PubMed Web of Science ®Google Scholar
• Soeiro-de-Souza MG, Pastorello BF, Leite Cda C, Henning A, Moreno RA, Garcia Otaduy MC. Dorsal anterior cingulate lactate and glutathione levels in euthymic bipolar I disorder: 1H-MRS study. Int J Neuropsychopharmacol. 2016;19:1–8.
   Web of Science ®Google Scholar
• Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ, et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol. 2010;177:575–85.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33:2551–65.
   PubMed Web of Science ®Google Scholar
• Baxter LR Jr, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, et al. Cerebral metabolic rates for glucose in mood disorders: studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry. 1985;42:441–7.
   PubMed Web of Science ®Google Scholar
• Mehrpooya M, Yasrebifar F, Haghighi M, Mohammadi Y, Jahangard L. Evaluating the effect of coenzyme Q10 Augmentation on treatment of bipolar depression: a double-blind controlled clinical trial. J Clin Psychopharmacol. 2018;38:460–6.
   PubMed Web of Science ®Google Scholar
• Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM.. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol. 2015;35:338–40.
   PubMed Web of Science ®Google Scholar
• Forester BP, Zuo CS, Ravichandran C, Harper DG, Du F, Kim S, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol. 2012;25:43–50.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Miguel MD, Fernández AAM, Carmona López IM, Garrido Maraver J, Cotán D, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010;12(R17).
   PubMedGoogle Scholar
• Cordero MD, Santos-García R, Bermejo-Jover D, Sánchez-Domínguez B, Jaramillo-Santos MR, Bullón P. Coenzyme Q10 in salivary cells correlate with blood cells in fibromyalgia: improvement in clinical and biochemical parameter after oral treatment. Clin Biochem. 2012;45:509–11.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. PLOS ONE. 2012;7(e35677).
   Google Scholar
• Cordero MD, Alcocer-Gómez E, de Miguel M, Cano-García FJ, Luque CM, Fernández-Riejo P, et al. Coenzyme Q10: A novel therapeutic approach for fibromyalgia? Case series with; 5, patients. Mitochondrion. 2011;11:623–5.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Alcocer-Gómez E, Cano-García FJ, de Miguel M, Campa F, Bonal P, et al. The effect of coenzyme Q10 on symptoms of mother and son with fibromyalgia syndrome. J Musculoskelet Pain. 2011;19:118–9.
   Web of Science ®Google Scholar
• Cordero MD, Díaz-Parrado E, Carrión AM, Alfonsi S, Sánchez-Alcazar JA, Bullón P, et al. Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? Antioxid Redox Signal. 2012;18:800–7.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Alcocer-Gómez E, de Miguel M, Culic O, Carrión AM, Alvarez-Suarez JM, et al. Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal. 2013;19:1356–61.
   PubMed Web of Science ®Google Scholar
• Alcocer-Gómez E, Sánchez-Alcázar JA, Cordero MD. Coenzyme q10 regulates serotonin levels and depressive symptoms in fibromyalgia patients: results of a small clinical trial. J Clin Psychopharmacol. 2014;34:277–8.
   PubMed Web of Science ®Google Scholar
• Alcocer-Gómez E, Culic O, Navarro-Pando JM, Sánchez-Alcázar JA, Bullón P. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients. CNS Neurosci Ther. 2017;23:188–9.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Alcocer-Gómez E, Culic O, Carrión AM, de Miguel M, Díaz-Parrado E, et al. NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10. Antioxid Redox Signal. 2014;20:1169–80.
   PubMed Web of Science ®Google Scholar
• Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett. 2009;30:462–9.
   PubMed Web of Science ®Google Scholar
• Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1–16.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Nojima J, Kajimoto O, Yamaguti K, Nakatomi Y, Kuratsune H, et al. Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. BioFactors Oxf Engl. 2016;42:431–40.
   PubMed Web of Science ®Google Scholar
• Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2017.
   Web of Science ®Google Scholar
• Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
   PubMed Web of Science ®Google Scholar
• Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14:365–76.
   PubMed Web of Science ®Google Scholar
• Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem. 2002;83:1241–51.
   PubMed Web of Science ®Google Scholar
• Somerville SM, Lahti AC, Conley RR, Roberts RC. Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response. Synapse. 2011;65:215–24.
   PubMed Web of Science ®Google Scholar
• Gubert C, Stertz L, Pfaffenseller B, Panizzutti BS, Rezin GT, Massuda R, et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J Psychiatr Res. 2013;47:1396–402.
   PubMed Web of Science ®Google Scholar
• Dror N, Klein E, Karry R, Sheinkman A, Kirsh Z, Mazor M, et al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry. 2002;7:995–1001.
   PubMed Web of Science ®Google Scholar
• Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry. 2012;73:506–12.
   PubMed Web of Science ®Google Scholar
• Kraya T, Neumann L, Paelecke-Habermann Y, Deschauer M, Stoevesandt D, Zierz S, et al. Cognitive impairment, clinical severity and MRI changes in MELAS syndrome. Mitochondrion. 2018. https://doi.org/10.1016/j.mito.2017.12.012.
   Web of Science ®Google Scholar
• Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 2006;47:1–7.
   PubMed Web of Science ®Google Scholar
• Whatley SA, Curti D, Marchbanks RM. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996;21:995–1004.
   PubMed Web of Science ®Google Scholar
• Imagawa M. Low erythrocyte coenzyme Q10 level in schizophrenic patients. Psychiatry Clin Neurosci. 1989;43:143–5.
   Google Scholar
• Dadheech G, Sharma P, Gautam S. Oxidative stress-induced response of some endogenous antioxidants in schizophrenia. Indian J Clin Biochem. 2012;27:278–83.
   PubMedGoogle Scholar
• Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721–8.
   PubMed Web of Science ®Google Scholar
• Matsuzawa D, Obata T, Shirayama Y, Knorr U, Greisen Soendergaard M, Henriksen T, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLOS ONE. 2008;3(e1944).
   PubMedGoogle Scholar
• Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Greisen Soendergaard M, Henriksen T, et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res. 2013;209:417–23.
   PubMed Web of Science ®Google Scholar
• Che Y. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci. 2010;35:296–302.
   PubMed Web of Science ®Google Scholar
• Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol. 2004:273–96.
   PubMed Web of Science ®Google Scholar
• Ross C, Biglan KM, Killoran A, Beal MF, Julian-Baros E, Yoritomo N, et al. Platform presentation: prequel-a multicenter phase ii study of coenzyme Q(10) in pre-manifest huntington disease. Neurotherapeutics. 2014;11(214).
   Google Scholar
• Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, et al. Plasma 8-hydroxy-2′-deoxyguanosine levels in huntington disease and healthy controls treated with coenzyme Q10. J Huntingt Dis. 2012;1:65–9.
   PubMedGoogle Scholar